Scientist, Oncology Biomarker Development
I am interested in translating clinical scientific insights back to the lab (in silico and traditional) to inform rational patient selection strategies for future biomarker-driven clinical trials. this includes both identification and characterization of novel molecular therapeutic targets and mechanisms of resistance to targeted therapies.
Immunogenomic Landscape of Pediatric Cancers
The study of a tumor’s immune repertoire includes an analysis of T cell receptors and B cell receptors that allow an immune system to adapt to changes and launch an immune system response. Using the Pediatric Brain Tumor Atlas, researchers will study the immune repertoire across tumor types which could lead to new immunotherapies.
All Brain Tumor Types
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test
Low-Grade Gliomas also called astrocytomas are the most common cancer of the central nervous system in children. They represent a heterogeneous group of tumors that can be discovered anywhere within the brain or spinal cord. Although surgical resection may be curative, up to 20% of children still su
Diffuse Intrinsic Pontine Glioma
A presumptive diagnosis of DIPG based on classic imaging features, in the absence of a histologic diagnosis, has been routinely employed. Increasingly however, histologic confirmation is obtained for both entry into research studies and molecular characterization of the tumor. New approaches with